An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer

Affiliations

Editorial

Muhammad Zubair Afzal et al. Ann Transl Med. 2019 Mar.

. 2019 Mar;7(Suppl 1):S53.

doi: 10.21037/atm.2019.03.09.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller SM, Gandhi L. Borghaei H, et al. J Thorac Oncol. 2019 Jan;14(1):124-129. doi: 10.1016/j.jtho.2018.08.004. Epub 2018 Aug 21. J Thorac Oncol. 2019. PMID: 30138764

1. Thunnissen E, van der Oord K, den Bakker M. Prognostic and predictive biomarkers in lung cancer. A review. Virchows Arch 2014;464:347-58. 10.1007/s00428-014-1535-4 - DOI - PubMed
1. Stewart DJ. Targeted therapy in non-small cell lung cancer. In: Kurzrock R, Markman M. editors. Targeted Cancer Therapy. NY: Springer, 2008:125-56.
1. Zukin M, Barrios CH, Pereira JR, et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non–small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 2013;31:2849-53. 10.1200/JCO.2012.48.1911 - DOI - PubMed
1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54. 10.1056/NEJMoa1200690 - DOI - PMC - PubMed
1. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28. 10.1056/NEJMoa1501824 - DOI - PubMed